GARP Research Of In Defense on Cepheid (CPHD); Franchise Remains Solid Plus Progress In Pipeline
Tweet
Share
E-mailGet Alerts CPHD Hot Sheet
Price: $52.95 --0%
Rating Summary:
11 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 2 | Down: 3 | New: 2
Rating Summary:
11 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 2 | Down: 3 | New: 2
Join SI Premium – FREE
GARP Research maintains a 'Buy' on Cepheid (NASDAQ: CPHD) price target of $36.00.
Analyst, Alastair Mackay, said, "Production woes sent the quarter’s gross margin down by 3.6 points y/y, prompting management to lower 2012 EPS guidance by 10%. Shares fell 6% on the news. However, the franchise remains solid, with commercial placements up, test kits selling strongly, and progress on the pipeline."
"The company has more than doubled revenue over the past four years, due mostly to the compelling performance of its tests for MRSA. We expect sales to double again over the next three years as Xpert MRSA gains CLIA-waived status, and as new kits reach the market. The catalog could include two dozen molecular assays by the end of our three-year investment horizon. Regulatory approvals of tests in advanced stages of development would more than double CPHD’s addressable market."
For an analyst ratings summary and ratings history on Cepheid click here. For more ratings news on Cepheid click here.
Shares of Cepheid closed at $35.72 yesterday.
Analyst, Alastair Mackay, said, "Production woes sent the quarter’s gross margin down by 3.6 points y/y, prompting management to lower 2012 EPS guidance by 10%. Shares fell 6% on the news. However, the franchise remains solid, with commercial placements up, test kits selling strongly, and progress on the pipeline."
"The company has more than doubled revenue over the past four years, due mostly to the compelling performance of its tests for MRSA. We expect sales to double again over the next three years as Xpert MRSA gains CLIA-waived status, and as new kits reach the market. The catalog could include two dozen molecular assays by the end of our three-year investment horizon. Regulatory approvals of tests in advanced stages of development would more than double CPHD’s addressable market."
For an analyst ratings summary and ratings history on Cepheid click here. For more ratings news on Cepheid click here.
Shares of Cepheid closed at $35.72 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
- Wayfair (W) PT Raised to $55 at TD Cowen
- Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
